Thus, post-stroke VEGF treatment may be counterproductive, a concern that is heightened by the lack of reporting positive results in such clinical trials (ClinicalTrials.gov identifiers: NCT02157896 and NCT00134433) (46). The gene discussed is VEGFA; the disease is stroke disorder.